person · Reporting owner

MCCLUNG JAMES A

Disclosed activity across 1 company

Tapewire entity: 157105
SEC CIK: 0001051331

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
SOLESENCE, INC.NANX · Entity 7041	Director	May 22, 2019	May 30, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

SOLESENCE, INC.

Report date May 22, 2019 · Filed May 30, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22	Direct	12,000	Reported balance After 2019-05-22 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2019-05-22 · Grant · Acquired 12,000 · Balance 12,000 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2021-01-31	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 12,000 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2022-08-07	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 12,000 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2023-02-14	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 12,000 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2024-02-13	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 12,000 F5: Beginning on this date, and subject to certain restrictions, the stock options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2025-02-18	Direct	10,800	Reported balance Holding disclosure · report date 2019-05-22 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 10,800 F6: Beginning on this date, and subject to certain restrictions, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23	Direct	9,720	Reported balance Holding disclosure · report date 2019-05-22 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 9,720 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.05 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.85 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2026-11-17	Direct	2,250	Reported balance Holding disclosure · report date 2019-05-22 · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · Balance 2,250 F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · Balance 12,000 F5: Beginning on this date, and subject to certain restrictions, the stock options vest in three equal annual installments.
Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23	Direct	12,000	Reported balance Holding disclosure · report date 2019-05-22 · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · Balance 12,000 F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
Common StockSEC Table I · non-derivative	IndirectBy Wife	30,071	Reported balance Holding disclosure · report date 2019-05-22 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 30,071
Common StockSEC Table I · non-derivative	Direct	17,582	Reported balance Holding disclosure · report date 2019-05-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 17,582
Deferred Common StockSEC Table II · derivative / convertible security	Direct	21,596	Reported balance Holding disclosure · report date 2019-05-22 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 21,596 F2: Each share of deferred common stock represents a right to receive one share of common stock. F3: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company. F4: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 21,596 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.

F2: Each share of deferred common stock represents a right to receive one share of common stock.

F3: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.

F4: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 21,596 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.

F5: Beginning on this date, and subject to certain restrictions, the stock options vest in three equal annual installments.

F6: Beginning on this date, and subject to certain restrictions, options vest in three equal annual installments.

F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 22, 2019 Filed May 30, 2019 20:06 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantCommon Stock (right to purchase) · Derivative	12,000	$0.51 Strike: $0.51	$6,120.00	Disclosure SEC source: 0001209191-19-033419 · doc4.xml · derivative · entry 19 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document
May 23, 2018 Filed May 24, 2018 22:30 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantCommon Stock (right to purchase) · Derivative	12,000	$0.82 Strike: $0.82	$9,840.00	Disclosure SEC source: 0001209191-18-033134 · doc4.xml · derivative · entry 18 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document
February 21, 2017 Filed Feb 22, 2017 22:01 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantCommon Stock (right to buy) · Derivative	12,000	$0.68 Strike: $0.68	$8,160.00	Disclosure SEC source: 0001209191-17-013349 · doc4.xml · derivative · entry 17 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-02-21 F5 · derivative.exercise_date: Beginning on this date, and subject to certain restrictions, the stock options vest in three equal annual installments. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$0.99 Strike: $0.99	$2,227.50	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 17 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$1.10 Strike: $1.10	$2,475.00	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 16 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$1.85 Strike: $1.85	$4,162.50	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 15 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$0.84 Strike: $0.84	$1,890.00	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 14 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$1.18 Strike: $1.18	$2,655.00	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 13 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$1.05 Strike: $1.05	$2,362.50	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 12 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	GrantStock Option (right to buy) · Derivative	2,250	$0.90 Strike: $0.90	$2,025.00	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 11 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 2,250 shares Expires 2026-11-17 F8 · derivative.exercise_price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. F8 · price: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99. Read SEC document
November 17, 2016 Filed Nov 21, 2016 14:44 UTC	SOLESENCE, INC. NANX · Entity 7041	Disposition to issuerStock Appreciation Right · Derivative	15,750	$1.18 Strike: $1.18	$18,585.00	Disclosure SEC source: 0001209191-16-151335 · doc4.xml · derivative · entry 5 MCCLUNG JAMES A · CIK 0001051331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,750 shares Expires not disclosed F5 · security: The stock appreciation rights that were to become payable upon the reporting person's termination of service as a director of the Company. 2,250 were issued 4/8/2009 at a conversion price of $0.90, 2,250 were issued 7/1/2009 at a conversion price of $1.05, 2,250 were issued 10/1/2009 at a conversion price of $1.18, 2,250 were issued 1/4/2010 at a conversion price of $0.84, 2,250 were issued 4/1/2010 at a conversion price of $1.85, 2,250 were issued 7/1/2010 at a conversion price of $1.10, and 2,250 were issued 10/1/2010 at a conversion price of $0.99. F5 · derivative.exercise_price: The stock appreciation rights that were to become payable upon the reporting person's termination of service as a director of the Company. 2,250 were issued 4/8/2009 at a conversion price of $0.90, 2,250 were issued 7/1/2009 at a conversion price of $1.05, 2,250 were issued 10/1/2009 at a conversion price of $1.18, 2,250 were issued 1/4/2010 at a conversion price of $0.84, 2,250 were issued 4/1/2010 at a conversion price of $1.85, 2,250 were issued 7/1/2010 at a conversion price of $1.10, and 2,250 were issued 10/1/2010 at a conversion price of $0.99. F5 · price: The stock appreciation rights that were to become payable upon the reporting person's termination of service as a director of the Company. 2,250 were issued 4/8/2009 at a conversion price of $0.90, 2,250 were issued 7/1/2009 at a conversion price of $1.05, 2,250 were issued 10/1/2009 at a conversion price of $1.18, 2,250 were issued 1/4/2010 at a conversion price of $0.84, 2,250 were issued 4/1/2010 at a conversion price of $1.85, 2,250 were issued 7/1/2010 at a conversion price of $1.10, and 2,250 were issued 10/1/2010 at a conversion price of $0.99. F5 · derivative.exercise_date: The stock appreciation rights that were to become payable upon the reporting person's termination of service as a director of the Company. 2,250 were issued 4/8/2009 at a conversion price of $0.90, 2,250 were issued 7/1/2009 at a conversion price of $1.05, 2,250 were issued 10/1/2009 at a conversion price of $1.18, 2,250 were issued 1/4/2010 at a conversion price of $0.84, 2,250 were issued 4/1/2010 at a conversion price of $1.85, 2,250 were issued 7/1/2010 at a conversion price of $1.10, and 2,250 were issued 10/1/2010 at a conversion price of $0.99. F5 · derivative.expiration_date: The stock appreciation rights that were to become payable upon the reporting person's termination of service as a director of the Company. 2,250 were issued 4/8/2009 at a conversion price of $0.90, 2,250 were issued 7/1/2009 at a conversion price of $1.05, 2,250 were issued 10/1/2009 at a conversion price of $1.18, 2,250 were issued 1/4/2010 at a conversion price of $0.84, 2,250 were issued 4/1/2010 at a conversion price of $1.85, 2,250 were issued 7/1/2010 at a conversion price of $1.10, and 2,250 were issued 10/1/2010 at a conversion price of $0.99. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.